BGLC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
BioNexus Gene Lab Corp (BGLC) is not a strong buy for a beginner, long-term investor at this time. The technical indicators are bearish, the financial performance is weak, and there are no positive catalysts or significant trading signals to justify an immediate investment. Holding off for now would be more prudent.
The MACD is below zero and negatively contracting, indicating a bearish momentum. RSI is neutral at 29.524, not signaling oversold or overbought conditions. Moving averages are bearish (SMA_200 > SMA_20 > SMA_5), and the price is below the pivot level of 2.359, suggesting downward pressure. Support is at 1.98, and resistance is at 2.737.
NULL identified. No recent news or significant trading trends from hedge funds or insiders.
also closed down by -1.54%, which could indicate a challenging market environment.
In Q3 2025, revenue dropped by -3.29% YoY to $2,543,823. Net income fell by -47.30% YoY to -$708,991, and EPS declined by -48.00% YoY to -0.39. However, gross margin improved by 19.66% YoY to 14.85%. Overall, the financial performance shows significant weakness.
No analyst ratings or price target changes available.
